Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Not waiting for the start of the annual J.P. Morgan Healthcare Conference, Eli Lilly announced it will acquire California-based Dermira, Inc. in an all-cash deal for $1.1 billion.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Company’s First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms
The Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.
The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic
Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019.
The two companies cited a lengthy regulatory approval process and “continued uncertainty” of the outcome of the merger as the primary reasons behind the termination of the deal.
The decision to file Chapter 11 followed a close examination of the company’s strategic options and current financing.
Parnell announces 2019 year-to-date revenue growth of 9% over the first 9 months of 2018, start of work on its new 2019 CMO contract, and updates to 2019 financial results.
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.